Facebook link Linked In link You Tube link

FCE Fusion: Careers. Collaboration. Connection.

FCE Fusion 1FCE Fusion 2FCE Fusion 3

FCE Fusion: Careers. Collaboration. Connection. (formerly Trainee Satellite Symposium)

Wednesday, June 22, 2016
12:00 pm – 2:00 pm EDT
Seaport World Trade Center – Cityview 2 (Plaza/Third Floor)
Boston, Massachusetts

Join Us

The FOCIS Centers of Excellence (FCEs) are a network of academic medical centers that focus on interdisciplinary and translational education and research. Within each FCE, trainee and fellow development is a top priority. 

FCE Fusion is a lunch and networking event at FOCIS 2016 where trainees present their work during the poster tour and receive mentoring and feedback from FCE directors. This year's program also features a career panel discussion aimed at providing trainees with an all-encompassing view of career opportunities available to them, including positions in industry, venture capital firms, and scientific journals. 

Participation in this symposium is limited to trainees who are competitively selected from their FCE.


12:00 - 12:15pm Networking

  • Hors-d'oeuvres and Beverages

12:15 - 12:20pm Welcome and Introduction

12:20 - 1:10pm Career Panel Discussion

  • Scott Plevy, MD, Janssen
  • Angela Colmone, PhD, Science Immunology
  • C. Garrison Fathman, MD, Stanford University School of Medicine
  • Stephan Gauldie, PHD, Back Bay Life Science Advisors
  • Jason P. Hafler, Sanofi-Genzyme BioVentures
  • Panel session moderated by Timothy B. Niewold, MD, Mayo Clinic

1:10 - 2:00pm Poster Tours

About the Career Opportunities Panelists

  • Scott Plevy, MD is a distinguished, board-certified gastroenterologist who comes to Janssen after a successful career in academia. He has been the lead investigator on multiple early-phase clinical trials and has performed translational research to advance the understanding of novel immunologic interventions. In addition, Scott has contributed to more than 80 peer-reviewed publications concentrating on inflammatory bowel disease (IBD). As IBD Disease Area Stronghold Leader, Scott is responsible for outlining strategies to advance new paradigms for treatment and intervention, collaborating with several internal groups to identify priority targets for drug discovery and development that will enhance the current IBD portfolio.
  • Angela Colmone, PhD, is the Editor of Science Immunology, with expertise in immunology, cancer biology, inflammation and fibrosis, and computational modeling. She received her Ph.D. in Immunology from The University of Chicago, where she studied immune cell development, response to infectious disease, and autoimmunity. After her graduate work, Angela pursued a postdoctoral fellowship that bridged cancer and stem cell biology, focusing on the interactions of cancer and stem cells in the tumor microenvironment. She then served as the Scientific Editor for The American Journal of Pathology and The Journal of Molecular Diagnostics, where she handled Review and Commentary solicitation and editing and led the public outreach initiative. Angela then joined the American Association for the Advancement of Science as a scientific editor, first with Science Translational Medicine and then with Science Immunology
  • C. Garrison Fathman, MD,Dr. C. Garrison Fathman, Professor of Medicine and Chief of the Division of Immunology and Rheumatology at Stanford University School of Medicine, also serves as Past Chairman of the Federation of Clinical Immunology Societies (FOCIS) and Director of the Center for Clinical Immunology at Stanford (CCIS). Dr. Fathman’s contributions in translational medicine in the areas of cellular and molecular immunology, as well as adoptive cellular gene therapy, have brought him international recognition. In particular, he is acclaimed for his establishment and exploitation of the technologies of antigen-specific T-cell cloning and adoptive cellular gene therapy, accomplishments that have facilitated a remarkable series of subsequent advances in understanding conventional immune response and treating autoimmune diseases. As Founder and Past Chairman of FOCIS, Dr. Fathman led an extremely successful international effort to acknowledge and develop the field of clinical immunology. As Director of the CCIS, the Stanford-based FOCIS Center of Excellence, Dr. Fathman has initiated multi-disciplinary studies to generate novel approaches for the treatment of autoimmune diseases, including insulin-dependent diabetes mellitus, rheumatoid arthritis, and multiple sclerosis. He has also developed state-of-the-art technologies of genomics, proteomics, and metabolomics to integrate approaches to diagnosis, prognosis, and therapy of these diseases.
  • Stephan Gauldie, PhD, joined Back Bay at its founding in 2010 and has been actively building the firm's consulting offering across company size, life science sector, and therapeutic area. His role places particular emphasis on Strategic Franchise Building, M&A and Licensing Strategy, Buy Side Diligence/Opportunity Assessment, and Liquidity Planning for Emerging Growth Companies. In addition to his senior consulting role, Stephan is a member of Back Bay's Financial Advisory team, providing market and scientific analytics to support both Sell Side and Buy Side engagements. Stephan has over 15 years of experience across drug discovery research, market analysis, and strategy consulting. Prior to joining Back Bay, he led the Commercial Research Group at Decision Resources and was a Principal Analyst at Wood Mackenzie, leading teams that covered mid-cap and large-cap US and EU-based pharmaceutical companies, as well as CNS/Pain and Immunology therapeutic areas. Stephan obtained his doctorate in Neuropharmacology from the University of Edinburgh Medical School, in collaboration with GlaxoSmithKline's Neurology and Gastrointestinal Center for Early Drug Discovery (CEDD), and completed a post-doctoral fellowship in the Department of Pharmacology at the same institution. Stephan also holds undergraduate degrees in Medicinal Chemistry and Psychology from Queen's University, Canada.
  • Jason P. Hafler is the Senior Director of Investments and Principal at Sanofi-Genzyme BioVentures. Jason joined Sanofi-Genzyme BioVentures in 2014 with a background in early stage biotech investing and transactions. Prior to SGBV, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space. Jason serves on the Board of NeuroVia Inc. and is a Board Observer for Navitor Pharmaceuticals. In addition, he is on the Board of Trustees at the Buckingham Browne and Nichols school and on the Board of Directors of The Magdalene College Foundation. Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Nominees Presenting their Research

Each FCE competitively selects up to two trainees to receive a travel award to attend FCE Fusion and the FOCIS Annual Meeting. At FCE Fusion, 28 FCE Nominated trainees will present their research: